Home › Funds › Tri Locum Partners LP › VRTX
Tri Locum Partners LP position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
Tri Locum Partners LP reported holding 201,791 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$100.2M, representing 12.33% of its reported portfolio and ranking #2 among its reported holdings. Tri Locum Partners LP has disclosed VRTX holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tri Locum Partners LP's VRTX position evolved
Tri Locum Partners LP first disclosed a stake in VRTX in Q1 2024 at 35,598 shares (US$14.9M). The position peaked in Q2 2026 at 201,791 shares, worth US$100.2M. Across 3 filings, Tri Locum Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 201,791 shares valued at US$100.2M — an increase of 72,477 shares quarter over quarter.. Notable position changes include a 56% increase in Q2 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 35.60K | $14.88M | New |
| Q1 2026 | 129.31K | $57.74M | New |
| Q2 2026 | 201.79K | $100.24M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Invesco Ltd 8.04M sh · $4.00B · Q2 2026
- LOOMIS SAYLES & CO L P 3.92M sh · $1.95B · Q2 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- Clearbridge Investments, LLC 2.34M sh · $1.16B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.17M sh · $1.08B · Q2 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on Tri Locum Partners LP
FAQ
How long has Tri Locum Partners LP held VRTX?
Tri Locum Partners LP has disclosed VRTX holdings in 3 of the last 10 reported quarters, going back to Q1 2024.
What is Tri Locum Partners LP's current position in VRTX?
As of Q2 2026, Tri Locum Partners LP holds 201.79K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $100.24M, representing 12.33% of its reported portfolio and ranking #2.
Has Tri Locum Partners LP been buying or selling VRTX?
In the latest 13F filing (Q2 2026), Tri Locum Partners LP increased its position in VRTX. The position peaked in Q2 2026 at 201.79K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.